Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
The Latest on: Cell replacement therapy
via Google News
The Latest on: Cell replacement therapy
- ASC Therapeutics Joins U.S. Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseaseson May 24, 2022 at 3:02 pm
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies has joined as a full ...
- Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022on May 20, 2022 at 4:38 am
Smart Immune, a clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of thymus-empowered T cell medicine, announced today it has ...
- Scientists explore mortality among women on hormone replacement therapy early in COVID-19 pandemicon May 20, 2022 at 3:35 am
A new study assessed the association of hormone replacement therapy or the use of the combined oral contraceptive pill with mortality among women with a previous history of COVID-19.
- Evotec, Sernova in partnership to develop beta cell diabetes therapyon May 19, 2022 at 7:13 am
Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova.
- Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meetingon May 18, 2022 at 3:02 am
Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced new data on its universal hepatocyte program in an oral presentation at the American ...
- Evotec, Sernova partner to develop implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabeteson May 17, 2022 at 9:30 pm
Evotec, Sernova partner to develop implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabetes: Hamburg, Germany Wednesday, May 18, 2022, 10:00 Hrs [I ...
- Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabeteson May 17, 2022 at 5:30 am
PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE; THE GOAL IS THE DEVELOPMENT AND C ...
- Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meetingon May 16, 2022 at 4:59 am
Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels ... week in poster sessions at the American Society of Gene and Cell Therapy ...
- San Diego’s Aspen Neuroscience lands $147M for Parkinson’s cell therapyon May 10, 2022 at 12:12 am
Aspen Neuroscience, a San Diego biotech that’s developing cell replacement therapy to treat Parkinson’s disease, has raised $147.5 million in a second round of venture capital funding. The investment ...
- FDA places hold on trial of novel cell therapy for type 1 diabeteson May 7, 2022 at 8:53 pm
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.
via Bing News